[Ip-health] KEI Comments on DHHS Session on WHA68, agenda item 14.1, regarding collection of economic data

Manon Ress manon.ress at keionline.org
Mon May 11 10:30:28 PDT 2015


KEI Comments on DHHS Session on WHA68, agenda item 14.1, regarding
collection of economic data

On Friday May 8, 2015, the US Department of Health and Human Services held
a listening session to solicit input on the agenda items for the upcoming
68th World Health Assembly. KEI delivered five interventions covering a
range of critical WHA topics. The full provisional agenda of the 68th WHA
can be accessed here:

Elizabeth Rajasingh presented the second intervention for KEI, addressing
agenda item 14.1 Monitoring the achievement of the health-related Millenium
Development Goals. The relevant WHO document is A68/13. Her full
intervention follows below:

Elizabeth Rajasingh, KEI, on Agenda Item 14.1
May 8, 2015

Good Morning, My name is Elizabeth Rajasingh and I am the Perls Research
and Policy Fellow at Knowledge Ecology International.

Under Agenda Item 14.1, Monitoring of the achievement of the health-related
Millennium Development Goals, the WHO recommits itself to providing access
to affordable essential medicines in developing countries. To achieve this,
the WHO must hold pharmaceutical companies accountable for the rising high
price of medicines and demand greater transparency about the cost of
research and development.

One of the greatest barriers in providing access is the high price of
medicines. The cost of the newest drugs for the treatment of cancer now
exceed $150,000 a year, and access is extremely unequal across the world.

The justification for the high prices is typically, if not always, based
upon claims by pharmaceutical companies that high prices are necessary to
reward the outlays and risks for research and development.

The evidence to substantiate these claims, however, is often lacking,
and/or controlled by drug company funded researchers and research centers.
There is also only limited information on other economic variables, such as
drug prices, revenues, per patient costs of clinical trials, and the role
of government subsidies for R&D, such as tax credits and research grants.

Several U.S. states, such as California, Massachusetts. North Carolina,
Oregon and Pennsylvania are considering legislation to require
pharmaceutical companies to disclose R&D costs, subsidies from government,
as well as other issues.

KEI asks that the WHO convene a meeting to address two issues.
First, what types of economic information should governments require
pharmaceutical companies to disclose? This data on R&D costs, research
subsidies, prices and sales should complement other data on the safety and
efficacy of products.

Second, there is a need to identify the types of economic data should be
collected and analyzed by the new global observatory for health R&D the WHO
is about to create.

This is not only our view. The New York Times editorial from May 5, 2015,
titled "Runaway Drug Prices," endorsed such legislation, noting that
"surely the public would benefit from increased transparency that might
deter the worst abuses."

If the WHO is expected to play a role in curbing the high cost of
medicines, it needs to have a strong basis of evidence and demand greater
transparency from the pharmaceutical industry.

More information about the Ip-health mailing list